BiotechBreakthroughs @BioBreakthrough

Joined February 2013

Tweets

1K
Followers

4K
Following

37
Likes

2

Marc Lehman @markflowchatter

2 months ago

William Blair calling "Bullshit" tonite and downgrading $INKT to Market Perform Old recirculated one patient data Looks like HC W will get the offering on Monday for keeping quiet earlier in the day

9 9 26 12K 7

BiotechBreakthroughs @BioBreakthrough

2 months ago

$INKT Bleeding lower after hours as sellers try to escape before the probable HCW cap raise hits the wires tonight/early next week. Target $10.

0 0 2 267 0

BiotechBreakthroughs @BioBreakthrough

2 months ago

$INKT BUYER BEWARE. HCW currently working stock in preparation for a PIPE likely in the $10-15 range. Chasers at current levels going to lose 3/4 of their investment imminently.

0 0 2 270 0

BiotechBreakthroughs @BioBreakthrough

2 months ago

$INKT OLD NEWS -- From May 15 press release: "A peer-reviewed publication expected in the first half of 2025 will detail a complete remission in a patient with metastatic testicular cancer treated in MiNK’s Phase 1 trial with a single infusion of agenT-797."

0 2 2 254 0

BiotechBreakthroughs @BioBreakthrough

2 months ago

$INKT CAUTION: Today's news is NOT NEW, previously reported in a press release on May 15. Company will use this unwarranted surge in shares to raise funds at steep discount.

0 0 5 632 0

BiotechBreakthroughs @BioBreakthrough

6 months ago

$KZIA URGENT BREAKING NEWS: $CMRX JUST ACQUIRED FOR $935 MILLION. Kazia market cap just over $4 million here. ***KAZIA LEAD DRUG IS USED IN COMBINATION THERAPY WITH CMRX LEAD DRUG*** As close to a no-brainer STRONG BUY RIGHT NOW in biotech as you get. pmc.ncbi.nlm.nih.gov/articles/PMC10…

1 2 4 1K 1

BiotechBreakthroughs @BioBreakthrough

7 months ago

$DWTX "Dogwood is Dogshit: Fair Value = 75 cents." Promoter Pump is over.. dump in progress. Don't get caught holding the bag.

0 1 0 483 0

BiotechBreakthroughs @BioBreakthrough

9 months ago

$KZIA $CMRX Dordaviprone works best in combination with Kazia's pax, so expect FDA to greenlight. As soon as traders connect the dots, Kazia shares will be re-rated much, much higher.

Evie Jackson @evierjackson

2 years ago

$KZIA $CMRX Dordaviprone works best in combination with Kazia's pax, so expect FDA to greenlight. As soon as traders connect the dots, Kazia shares will be re-rated much, much higher.

7 22 52 55K 6

1 0 1 2K 0

Evie Jackson @evierjackson

2 years ago

Incredibly proud to share the latest work from #DunLab, published in #CancerResearch! We highlight the combination of ONC201 and paxalisib for the treatment of DMG, the preclinical data informing PNOC022. Follow this tweetorial for a summary: (1/10) aacrjournals.org/cancerres/arti…

7 22 52 55K 6

BiotechBreakthroughs @BioBreakthrough

9 months ago

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalization, similar PR will launch shares to $20+ instantly.

1 0 1 1K 0

BiotechBreakthroughs @BioBreakthrough

9 months ago

$KZIA $CMRX Kazia meets with FDA this month to discuss AA. Given current market capitalizaiton, s$similar PR will launch shares to $20+ instantly.

0 0 1 684 0

BiotechBreakthroughs @BioBreakthrough

9 months ago

$KZIA a Strong Buy on the $CMRX move. cancer.gov/research/parti… pubmed.ncbi.nlm.nih.gov/37195023/

0 0 1 529 0

BiotechBreakthroughs @BioBreakthrough

10 months ago

$KZIA Clueless low volume sellers in this biotech/healthcare "RFK panic" may wish to consider that GBM took the life of his uncle.

0 0 2 579 0

Ozmosi @OzmosiHealth

10 months ago

$KZIA Kazia Therapeutics schedules Type C meeting with FDA to discuss potential next steps for Paxalisib in treating newly diagnosed Glioblastoma Multiforme. More Info: pryzm.ozmosi.com/product/14290 $XBI $IBB $XPH $PPH

0 1 2 515 1

Download Image

BiotechBreakthroughs @BioBreakthrough

10 months ago

$VCNX up 50%, $MNPR down 40% since this post a week ago.

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX up 50%, $MNPR down 40% since this post a week ago.

0 0 0 2K 2

1 0 1 981 0

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX Tiny biotech trading under cash foreshadowing PROMISING ALZHEIMER'S DATA in exactly one week. BUY $VCNX, SELL $MNPR is the prudent trade.

0 0 0 2K 2

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX Risk-reward here is EXPONENTIALLY more favorable than buying $MNPR. Monopar simply paying for the right to use a drug (really shouldn't even be trading up on this). Expecting a much more significant partnership announcement for Vaccinex. $VCNX current mkt cap 1/10 of $MNPR.

0 0 3 839 1

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX Shares trade under cash, majority of float owned by insiders. CEO has purchased millions of shares. $MNPR

0 0 0 614 0

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX MAJOR PARTNERSHIP ANNOUNCEMENT implied in recent PR ... the same news that ignited $MNPR

0 0 2 709 0

BiotechBreakthroughs @BioBreakthrough

11 months ago

$VCNX VACCINEX TO REPORT PROMISING NEW EFFICACY DATA AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE one week from today. $VCNX the next $MNPR?